NIFDS seeking to ensure bioequivalence of generic drugs

Published: 2013-05-28 06:56:00

Updated: 2013-05-28 06:56:00

The National Institute of Food and Drug Safety Evaluation (NIFDS) plans to introduce a regulation that a generic drug manufacturers must provide a full description of the bioequivalence testing results related to a generic product, such as pharmacokinetic profiles (AUC and Cmax), to ensure the fi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK